TY - JOUR
T1 - Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects
T2 - A Systematic Review
AU - Chen, Yi Hsuan
AU - Molenaar, Dominique
AU - Uyl-de Groot, Carin A.
AU - van Vulpen, Marco
AU - Blommestein, Hedwig M.
N1 - Funding Information: Acknowledgments: The research is supported by Medical Delta, scientific HollandPTC Medical Delta program on HTA value proposition. The authors would like to acknowledge the assistance of Wichor M. Bramer for his help with building the search strategy. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Background: Despite the need for a proper economic evaluation of new radiotherapies, the economic burden of radiotherapy-induced adverse effects remains unclear. A systematic review has been conducted to identify the existing evidence of healthcare resource use and costs related to radiotherapy-induced adverse effects and also to provide recommendations for including this evidence in economic evaluations. Methods: This systematic review of healthcare resource use and/or medical costs related to radiotherapy-induced adverse effects was performed up until 2020, focusing on patients with head and neck cancer, brain cancer, prostate cancer, eye cancer and breast cancer. Results: Resource use for treating the same adverse effects varied considerably across studies; for instance, the cost for mucositis ranged from USD 2949 to USD 17,244. This broad range could be related to differences in (1) severity of adverse effects in the study population, (2) study design, (3) cost estimation approach and (4) country and clinical practice. Conclusions: Our findings revealed unignorable differences for the same adverse effects, which implied that the potential for the economic burden of adverse effects was being overestimated or underestimated in economic evaluation for radiotherapy.
AB - Background: Despite the need for a proper economic evaluation of new radiotherapies, the economic burden of radiotherapy-induced adverse effects remains unclear. A systematic review has been conducted to identify the existing evidence of healthcare resource use and costs related to radiotherapy-induced adverse effects and also to provide recommendations for including this evidence in economic evaluations. Methods: This systematic review of healthcare resource use and/or medical costs related to radiotherapy-induced adverse effects was performed up until 2020, focusing on patients with head and neck cancer, brain cancer, prostate cancer, eye cancer and breast cancer. Results: Resource use for treating the same adverse effects varied considerably across studies; for instance, the cost for mucositis ranged from USD 2949 to USD 17,244. This broad range could be related to differences in (1) severity of adverse effects in the study population, (2) study design, (3) cost estimation approach and (4) country and clinical practice. Conclusions: Our findings revealed unignorable differences for the same adverse effects, which implied that the potential for the economic burden of adverse effects was being overestimated or underestimated in economic evaluation for radiotherapy.
KW - adverse effect
KW - health care cost
KW - health resource
KW - radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85129916080&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/cancers14102444
DO - https://doi.org/10.3390/cancers14102444
M3 - Review article
C2 - 35626049
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 10
M1 - 2444
ER -